{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:44:54Z","timestamp":1779914694957,"version":"3.53.1"},"reference-count":81,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qatar Biomedical Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Excess hepatic lipid accumulation is the hallmark of non-alcoholic fatty liver disease (NAFLD), for which no medication is currently approved. However, glucagon-like peptide-1 receptor agonists (GLP-1RAs), already approved for treating type 2 diabetes, have lately emerged as possible treatments. Herein we aim to investigate how the GLP-1RA exendin-4 (Ex-4) affects the microRNA (miRNAs) expression profile using an in vitro model of steatosis. Total RNA, including miRNAs, was isolated from control, steatotic, and Ex-4-treated steatotic cells and used for probing a panel of 799 highly curated miRNAs using NanoString technology. Enrichment pathway analysis was used to find the signaling pathways and cellular functions associated with the differentially expressed miRNAs. Our data shows that Ex-4 reversed the expression of a set of miRNAs. Functional enrichment analysis highlighted many relevant signaling pathways and cellular functions enriched in the differentially expressed miRNAs, including hepatic fibrosis, insulin receptor, PPAR, Wnt\/\u03b2-Catenin, VEGF, and mTOR receptor signaling pathways, fibrosis of the liver, cirrhosis of the liver, proliferation of hepatic stellate cells, diabetes mellitus, glucose metabolism disorder and proliferation of liver cells. Our findings suggest that miRNAs may play essential roles in the processes driving steatosis reduction in response to GLP-1R agonists, which warrants further functional investigation.<\/jats:p>","DOI":"10.3390\/ijms241411606","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:47:38Z","timestamp":1689727658000},"page":"11606","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-291X","authenticated-orcid":false,"given":"Olfa","family":"Khalifa","sequence":"first","affiliation":[{"name":"Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ouararhni","sequence":"additional","affiliation":[{"name":"Genomics Core Facility, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaoula","family":"Errafii","sequence":"additional","affiliation":[{"name":"African Genome Center, Mohammed VI Polytechnic University (UM6P), Ben Guerir 43151, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-1091","authenticated-orcid":false,"given":"Nehad M.","family":"Alajez","sequence":"additional","affiliation":[{"name":"Translational Cancer and Immunity Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar"},{"name":"College of Health & Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5060-916X","authenticated-orcid":false,"given":"Abdelilah","family":"Arredouani","sequence":"additional","affiliation":[{"name":"Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar"},{"name":"College of Health & Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., and Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep4.1618","article-title":"Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting","volume":"5","author":"Lai","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kitade, H., Chen, G., Ni, Y., and Ota, T. (2017). Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients, 9.","DOI":"10.3390\/nu9040387"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: A patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.3748\/wjg.v20.i18.5320","article-title":"Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities","volume":"20","author":"Shaker","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: Current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yoo, E.R., Sallam, S., Perumpail, B.J., Iqbal, U., Shah, N.D., Kwong, W., Cholankeril, G., Kim, D., and Ahmed, A. (2018). When to Initiate Weight Loss Medications in the NAFLD Population. Diseases, 6.","DOI":"10.3390\/diseases6040091"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3945\/an.116.013730","article-title":"Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease","volume":"8","author":"Hsu","year":"2017","journal-title":"Adv. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mantovani, A., and Dalbeni, A. (2021). Treatments for NAFLD: State of Art. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052350"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3727\/105221617X15124844266408","article-title":"The Effects of Physical Exercise on Fatty Liver Disease","volume":"18","author":"Sud","year":"2018","journal-title":"Gene Expr. J. Liver Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cld.2017.08.012","article-title":"Current Treatment of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis","volume":"22","author":"Hung","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic Fatty Liver Disease and Obesity Treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr. Obes. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/s41598-022-06143-5","article-title":"Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt\/-catenin signaling pathway","volume":"12","author":"Khalifa","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103382","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1242\/jcs.099200","article-title":"MicroRNAs and their roles in aging","volume":"125","author":"Slack","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MOL.0000000000000420","article-title":"MicroRNAs and lipid metabolism","volume":"28","author":"Aryal","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.7150\/ijbs.59588","article-title":"MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"17","author":"Fang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.trsl.2015.04.014","article-title":"High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis","volume":"166","author":"Leti","year":"2015","journal-title":"Transl. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.numecd.2016.08.004","article-title":"Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications","volume":"26","author":"Ragusa","year":"2016","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Okamoto, K., Koda, M., Okamoto, T., Onoyama, T., Miyoshi, K., Kishina, M., Kato, J., Tokunaga, S., Sugihara, T.A., and Hara, Y. (2016). A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154676"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1386-6346(01)00172-3","article-title":"Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model","volume":"23","author":"Okamoto","year":"2002","journal-title":"Hepatol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Errafii, K., Khalifa, O., Al-Akl, N.S., and Arredouani, A. (2022). Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051020"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Khalifa, O., HMroue, K., Mall, R., Ullah, E., SAl-Akl, N., and Arredouani, A. (2022). Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102652"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DMSO.S146339","article-title":"Obesity and nonalcoholic fatty liver disease: Current perspectives","volume":"11","author":"Sarwar","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fendo.2018.00649","article-title":"Future Perspectives on GLP-1 Receptor Agonists and GLP-1\/glucagon Receptor Co-agonists in the Treatment of NAFLD","volume":"9","author":"Seghieri","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"609110","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD","volume":"107","author":"Cusi","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1060028020935105","article-title":"A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101970","DOI":"10.1016\/j.clinre.2022.101970","article-title":"Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"46","author":"Zafar","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000370","DOI":"10.1136\/bmjgast-2019-000370","article-title":"Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis","volume":"7","author":"Yokomori","year":"2020","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting","volume":"48","author":"Waser","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"527059","DOI":"10.3389\/fmed.2020.527059","article-title":"miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease","volume":"7","author":"Escribano","year":"2020","journal-title":"Front. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lin, H.Y., Yang, Y.L., Wang, P.W., Wang, F.S., and Huang, Y.H. (2020). The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond. Cells, 9.","DOI":"10.3390\/cells9041041"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/gutjnl-2018-318146","article-title":"miRNAs and NAFLD: From pathophysiology to therapy","volume":"68","author":"Gjorgjieva","year":"2019","journal-title":"Gut"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6161694","DOI":"10.1155\/2022\/6161694","article-title":"Noncoding RNAs Associated with PPARs in Etiology of MAFLD as a Novel Approach for Therapeutics Targets","volume":"2022","author":"Kazeminasab","year":"2022","journal-title":"PPAR Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"Jansson","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8822859","DOI":"10.1155\/2020\/8822859","article-title":"Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers","volume":"2020","author":"Khalifa","year":"2020","journal-title":"Dis. Markers"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Inomata, Y., Oh, J.W., Taniguchi, K., Sugito, N., Kawaguchi, N., Hirokawa, F., Lee, S.W., Akao, Y., Takai, S., and Kim, K.P. (2022). Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095230"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"803445","DOI":"10.3389\/fphys.2022.803445","article-title":"MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","article-title":"Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver","volume":"424","author":"Yamada","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00535-014-0932-4","article-title":"Antitumor function of microRNA-122 against hepatocellular carcinoma","volume":"49","author":"Nakao","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4254\/wjh.v10.i10.662","article-title":"Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis","volume":"10","author":"Lin","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.toxlet.2022.09.008","article-title":"miR-345-5p curbs hepatic stellate cell activation and liver fibrosis progression by suppressing hypoxia-inducible factor-1alpha expression","volume":"370","author":"Wang","year":"2022","journal-title":"Toxicol. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Feng, J., Qiu, S., Zhou, S., Tan, Y., Bai, Y., Cao, H., Guo, J., and Su, Z. (2022). mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169196"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"174857","DOI":"10.1016\/j.ejphar.2022.174857","article-title":"mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis","volume":"921","author":"Arora","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mesarwi, O.A., Shin, M.K., Bevans-Fonti, S., Schlesinger, C., Shaw, J., and Polotsky, V.Y. (2016). Hepatocyte Hypoxia Inducible Factor-1 Mediates the Development of Liver Fibrosis in a Mouse Model of Nonalcoholic Fatty Liver Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168572"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14735","DOI":"10.1002\/jcb.28734","article-title":"Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN\/p65 signaling pathway","volume":"120","author":"Han","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"753268","DOI":"10.3389\/fmed.2021.753268","article-title":"Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis","volume":"8","author":"Holzner","year":"2021","journal-title":"Front. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Okamoto, K., Koda, M., Okamoto, T., Onoyama, T., Miyoshi, K., Kishina, M., Matono, T., Kato, J., Tokunaga, S., and Sugihara, T. (2020). Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0219412"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.15252\/embj.201490464","article-title":"microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis","volume":"34","author":"Rose","year":"2015","journal-title":"EMBO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"720900","DOI":"10.3389\/fcell.2021.720900","article-title":"Lack of miR-379\/miR-544 Cluster Resists High-Fat Diet-Induced Obesity and Prevents Hepatic Triglyceride Accumulation in Mice","volume":"9","author":"Cao","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-022-00089-w","article-title":"MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db\/db mice via STAT1\/HMGCS1 axis","volume":"3","author":"Dong","year":"2022","journal-title":"Mol. Biomed."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wang, C.H., Liu, H.M., Chang, Z.Y., Huang, T.H., and Lee, T.Y. (2021). Losartan Prevents Hepatic Steatosis and Macrophage Polarization by Inhibiting HIF-1\u03b1 in a Murine Model of NAFLD. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157841"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1165\/rcmb.2020-0492OC","article-title":"Hepatocyte HIF-1 and Intermittent Hypoxia Independently Impact Liver Fibrosis in Murine Nonalcoholic Fatty Liver Disease","volume":"65","author":"Mesarwi","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.gastrohep.2020.09.014","article-title":"Silencing HIF-1\u03b1 aggravates non-alcoholic fatty liver disease in vitro through inhibiting PPAR-\u03b1\/ANGPTL4 singling pathway","volume":"44","author":"He","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Seo, M.H., Lee, J., Hong, S.W., Rhee, E.J., Park, S.E., Park, C.Y., Oh, K.W., Park, S.W., and Lee, W.Y. (2016). Exendin-4 Inhibits Hepatic Lipogenesis by Increasing \u03b2-Catenin Signaling. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166913"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1210\/en.2012-1518","article-title":"A potential role of progestin-induced laminin-5\/\u03b16-integrin signaling in the formation of side branches in the mammary gland","volume":"153","author":"Meyer","year":"2012","journal-title":"Endocrinology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10799893.2020.1726952","article-title":"Inevitable role of TGF-\u03b21 in progression of nonalcoholic fatty liver disease","volume":"40","author":"Nair","year":"2020","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., and Wahli, W. (2020). Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells, 9.","DOI":"10.3390\/cells9071638"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"952734","DOI":"10.1155\/2009\/952734","article-title":"PPAR\/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease","volume":"2009","author":"Hardwick","year":"2009","journal-title":"PPAR Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100714","DOI":"10.1016\/j.jbc.2021.100714","article-title":"NF-\u03baB p65 regulates hepatic lipogenesis by promoting nuclear entry of ChREBP in response to a high carbohydrate diet","volume":"296","author":"Daniel","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/gut.2009.190801","article-title":"Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease","volume":"59","author":"Dongiovanni","year":"2010","journal-title":"Gut"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"472432","DOI":"10.1155\/2013\/472432","article-title":"Roles for PI3K\/AKT\/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease","volume":"2013","author":"Matsuda","year":"2013","journal-title":"ISRN Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2147\/DMSO.S206867","article-title":"Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2\/PI3K\/Akt signaling pathway","volume":"12","author":"Yang","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.gastro.2007.10.010","article-title":"PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65\/mTOR-dependent mechanism","volume":"134","author":"Vinciguerra","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"G298","DOI":"10.1152\/ajpgi.00346.2014","article-title":"Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis","volume":"308","author":"Dattaroy","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Friedman","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3892\/etm.2016.3069","article-title":"Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG(2) cells: An in vitro model of non-alcoholic fatty liver disease","volume":"11","author":"Alkhatatbeh","year":"2016","journal-title":"Exp. Ther. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11606\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:14:16Z","timestamp":1760127256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":81,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411606"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411606","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}